Discover 127 paid clinical trials in Chattanooga, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 127
Active & Responsive
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
Location: Chattanooga TN, Atlanta GA, Louisville KY,
Sponsor: GT Medical Technologies, Inc.
Sex: All
Age: 0+
Code: NCT04427384
Recruiting
Active & Responsive
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
for
Migraine
Location: Chattanooga TN, Huntsville AL, Knoxville TN, Atlanta GA,
Sponsor: AbbVie
Sex: Female
Age: 18+
Code: NCT06417775
Phase3, Recruiting
Active & Responsive
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
for
Hypothyroidism
Location: Chattanooga TN, Canton GA, Roswell GA, Knoxville TN,
Sponsor: AbbVie
Sex: All
Age: 18 - 70+
Code: NCT06345339
Phase2, Phase3, Recruiting
Active & ResponsiveNew
Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer
for
Lung Cancer - Non Small Cell Squamous,
Location: Chattanooga TN, Nashville TN, Fairfax VA
Sponsor: Merus N.V.
Sex: All
Age: 18+
Code: NCT07353957
Phase2, Recruiting
Active & Responsive
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
for
Platinum-resistant Ovarian Cancer,
Location: Chattanooga TN, Atlanta GA, Charlotte NC, Kettering OH,
Sponsor: Genelux Corporation
Sex: Female
Age: 18+
Code: NCT05281471
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis